



ATTORNEY DOCKET 14945.0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Simon BENITA et al

Confirmation No. 4640

Serial No. 10/787,122

Filed: February 27, 2004

For: DRUG DELIVERY SYSTEM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR §1.56, and in accordance with 37 CFR §§1.97 and 1.98, Applicants, through the undersigned attorney, submit this Information Disclosure Statement.

The references listed on attached Form PTO-1449 and submitted herewith were cited in the European Search Report dated August 26, 2004 in connection with the basic European application, No. 04290427.6. US 2002106324 is the US equivalent of WO 01/52889.

In accordance with 37 CFR §1.97(b)(3), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is required.

Respectfully submitted,

D. Douglas Price  
Reg. No. 24,514

STEPTOE & JOHNSON LLP  
1330 Connecticut Ave., N.W.  
Washington, D.C. 20036  
(202) 429-6748

FORM 1449 (S&amp;J Version)

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Docket No.: 14945.0001

Applicant: Simon BENITA et al

Application No.: 10/787,122

Filing Date: February 27, 2004

Examiner

Group Art Unit:

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document No.	Date MM/YYYY	Inventor	Class	Subclass	Filing Date If Appropriate
	2002106324	8/8/2002	Kadouche et al			

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Document No.	Date MM/YYYY	Country	Class	Subclass	Translation	
						Yes	No
	WO 01/52889	7/26/01	WIPO				x
	WO 95/03829	2/9/1995	WIPO				
	WO 93/18852	9/30/1993	WIPO				

**OTHER DOCUMENTS**

Examiner's Initials*	Include author, title of article, title of item (book, journal, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Yang, S. et al, "Enhanced Absorption and Drug Targeting by Positively Charged Submicron Emulsions," Drug Development Research, Vol. 50, No. 3/4, July 2000, pp. 476-486
	Kirpotin, D. et al, "Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells <i>in Vitro</i> ," Biochemistry, Vol. 36, No. 1, 1997, pp. 66-75
	Martin, F. et al, "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles," The Journal of Biological Chemistry, Vol. 257, No. 1, January 10, 1982, pp. 286-288
	Coppola, D., "Eye-Catching Delivery Formulation - Cationic Emulsions Target Ophthalmologic Medicines," Pharmaceutical Technology, Vol. 28, May 2004, pp. 15, 102, 113.

Examiner's  
Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.